Form 4: Director Spencer Berthelsen Executes IONS Stock Sale

Ionis Pharmaceuticals Director Spencer R. Berthelsen exercised options and sold 8,000 shares of common stock.

Summary

• Director Spencer R. Berthelsen exercised 8,000 stock options at a strike price of $24.42 per share.
• Following the exercise, the director sold 8,000 shares of common stock at a market price of $75.67 per share.
• The transactions were executed on June 1, 2026, pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
• The director's direct beneficial ownership in Ionis Pharmaceuticals stands at 156,013 shares post-transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is a routine administrative action for corporate insiders.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.

Negatives

• The director reduced his direct equity stake in the company by 8,000 shares.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via pre-arranged 10b5-1 plans is a standard corporate governance practice for executives and directors to manage personal liquidity without triggering market concerns regarding material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to conduct orderly divestments of equity compensation.

Related Party Transactions

• The reporting person holds 70 shares indirectly through his daughter, for which he disclaims beneficial ownership.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Option Exercise, Director Transaction